Outcomes delivered: from extreme to intermediate risk patient cohorts, four new compelling TAVI clinical study results

With an unrestricted educational grant from MEDTRONIC

Learning Objectives

  • To gain new clinical insights from the first time release of the 2-year data of the CoreValve ADVANCE study and the first release of the CoreValve ADVANCE II study results
  • To learn from the Corevalve US Pivotal Extreme and high-risk study data
  • To appraise Medtronic's Evolut R recapturable technology CE mark study 30-day results

Presentations available when logged in:

  • Introduction and objectives
  • Latest findings from the CoreValve ADVANCE study: 2-year results
  • New insights from the CoreValve US Pivotal Trial Extreme Risk and high-risk data
  • Procedural advancement: CoreValve Advance II study findings
  • Assessing the next generation platform: 30-day results from the CoreValve Evolut R study
  • Take-home message